TNF and psoriasis: Across nine adults with moderate-to-severe psoriasis treated with a TNF-α inhibitor, paired analyses (Wilcoxon signed-rank, two-sided α = 0.05) demonstrated a marked clinical improvement over 12 weeks alongside the objective recovery of skin barrier function.